Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia: supplementary data

Aim: This study evaluates the cost–effectiveness of imipenem/cilastatin/relebactam (IMI/REL) for treating

hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in an

‘early adjustment prescribing scenario’. Methods: An economic model was constructed to compare two

strategies: continuation of empiric piperacillin/tazobactam (PIP/TAZ) versus early adjustment to IMI/REL.

A decision tree was used to depict the hospitalization period, and a Markov model used to capture longterm

outcomes. Results: IMI/REL generated more quality-adjusted life years than PIP/TAZ, at an increased

cost per patient. The incremental cost–effectiveness ratio of $17,529 per QALY is below the typical US

willingness-to-pay threshold. Conclusion: IMI/RELmay represent a cost-effective treatment for payers and

a valuable option for clinicians, when considered alongside patient risk factors, local epidemiology, and

susceptibility data.